Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D derivatives for antiproteinuric effects in chronic kidney disease
2010-024023-25Phase 3Active
- Sponsor
- Lorenzo Victor, PhD
- Start
- Jul 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of paricalcitol, calcifediol and doxorubicin in chronic kidney disease (CKD) and proteinuria (4 arms), sponsored by Lorenzo Victor, PhD. Primary endpoint: Primary antiproteinuric effect. Started Jul 2011; status: active.
02
Drugs
paricalcitolcalcifedioldoxorubicin
03
Conditions
chronic kidney disease (CKD)proteinuria
Beyond the preview
Go deeper on 2010-024023-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024023-25.